Dengue fever, caused by a flavivirus named DENV, is a major global health challenge, risking almost half of the world's population. Since the early 20th century, the scientific community has faced ...

The study is expected to begin in the first quarter of 2027 & enrol around 1,000 patients in Brazil, Malaysia & Thailand. SII ...

The Food and Drug Monitoring Agency (BPOM) stated that the launch of an mRNA-based dengue vaccine prototype demonstrates ...

The world's first single-dose vaccine to prevent dengue fever has been approved for licensure in one of the largest countries affected by the disease, following 16 years of research contributions by ...

Consultant Paediatrician and Founder Clinical Head of the Centre for Clinical Management of Dengue & Dengue Haemorrhagic Fever in Negombo, Dr. Lakkumar Fernando, said an internationally approved ...

The first-ever vaccine against dengue fever, which affects up to 400 million people per year, will be publicly available for the first time after being cleared for use in Mexico, French manufacturer ...

ICMR and Panacea Biotec conduct third phase trials for indigenous dengue vaccine in India with promising results.

LONDON (Reuters) - France's Sanofi-Aventis is partnering with an international vaccine group to speed the adoption of its experimental dengue fever vaccine, which is currently in late-stage ...

Dengue fever caused by a flavivirus named DENV is a major global health challenge, risking almost half of the world's population. Since the early 20 th century, the scientific community has faced ...

Data from 1,028 people vaccinated with TAK-003 in Catalonia suggests that the dengue vaccine has a good tolerability profile in routine clinical practice among travelers from regions where dengue is ...

MOSCOW, June 24. /TASS/. Preclinical studies of the dengue fever vaccine have demonstrated its safety, immunogenicity and protective efficacy, head of the Federal Medical and Biological Agency ...